Literature DB >> 3153280

Recent advances and controversies in childhood renal osteodystrophy.

O Mehls1, I B Salusky.   

Abstract

Renal osteodystrophy starts very early in chronic renal failure. Although vitamin D levels are normal in patients with 70-80% function, the levels are not appropriate to the prevailing biochemical milieu. Renal osteodystrophy may contribute to renal growth failure but a correlation between the degree of renal osteodystrophy and growth failure is not observed. Catch-up growth cannot be obtained over a longer period of time with vitamin D. The main reason for osteomalacia is Al intoxication. Aluminium osteopathy is more common in pediatric renal patients than anticipated. The mechanism whereby Al produces its effect on bone is uncertain. Guidelines for the diagnosis and therapy of renal osteopathy are presented. Prophylaxis of renal osteopathy can be attempted by phosphate restriction and/or vitamin D and by avoiding Al-containing drugs. All vitamin D compounds can be used for treatment and all have their advantages and disadvantages.

Entities:  

Mesh:

Year:  1987        PMID: 3153280     DOI: 10.1007/bf00849295

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  100 in total

1.  The hydroxyproline content of plasma of patients with impaired renal function.

Authors:  W Hart; S A Duursma; W J Visser; L K Njio
Journal:  Clin Nephrol       Date:  1975       Impact factor: 0.975

2.  The renal handling of parathyroid hormone. Role of peritubular uptake and glomerular filtration.

Authors:  K J Martin; K A Hruska; J Lewis; C Anderson; E Slatopolsky
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

3.  Unique biosynthesis by kidney of a biological active vitamin D metabolite.

Authors:  D R Fraser; E Kodicek
Journal:  Nature       Date:  1970-11-21       Impact factor: 49.962

Review 4.  Aluminum.

Authors:  A C Alfrey
Journal:  Adv Clin Chem       Date:  1983       Impact factor: 5.394

5.  25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity.

Authors:  C B Langman; A T Mazur; R Baron; M E Norman
Journal:  J Pediatr       Date:  1982-05       Impact factor: 4.406

6.  Circulating vitamin D metabolite concentrations in childhood renal diseases.

Authors:  R W Chesney; A J Hamstra; R B Mazess; P Rose; H F DeLuca
Journal:  Kidney Int       Date:  1982-01       Impact factor: 10.612

7.  Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.

Authors:  J W Coburn; A S Brickman; D J Sherrard; F R Singer; E G Wong; D J Baylink; A W Norman
Journal:  Proc Eur Dial Transplant Assoc       Date:  1977

8.  Dialysis encephalopathy in a non-dialysed uraemic boy treated with aluminium hydroxide orally.

Authors:  E Nathan; S E Pedersen
Journal:  Acta Paediatr Scand       Date:  1980-11

9.  Interrelationship of serum 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D in juvenile renal osteodystrophy after therapy with 25-hydroxyvitamin D3.

Authors:  A Taylor; M E Norman
Journal:  Metab Bone Dis Relat Res       Date:  1982

10.  Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency.

Authors:  A A Portale; B E Booth; H C Tsai; R C Morris
Journal:  Kidney Int       Date:  1982-04       Impact factor: 10.612

View more
  3 in total

Review 1.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

2.  Alphacalcidol oral pulses normalize uremic hyperparathyroidism prior to dialysis.

Authors:  M Ala-Houhala; C Holmberg; K Rönnholm; A Paganus; J Laine; O Koskimies
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

3.  Intramuscular calcitriol for uraemic children with severe hyperparathyroidism and hypercalcaemia.

Authors:  A Claris-Appiani; G L Ardissino; M C Tischer; A Bettinelli; A S Tirelli; V Daccò; G Castiglioni; F Pecchio; M Cunazza; B M Assael
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.